Besides seroprotection against the vaccine strains, the vast majority of volunteers also showed neutralizing antibodies against the five heterologous test strains of GI–GIV. The seroprotection rates after the heterologous JE-VC booster were comparable with those recorded after a booster vaccine homologous to the click here primary series. It is noteworthy that, in contrast to the varying seroconversion rates observed after the JE-VC primary series, the cross-protection rates for JE-MB-primed subjects were around 90% both after a homologous and a heterologous booster.

Taken together, these results further support the use of a single dose of JE-VC for boosting JE-MB immunity, suggesting that the interval to a second booster dose may be extended to two years or even longer. No data, however, exist as yet on the longevity of cross-protection beyond two years. Among travelers primed with JE-VC, seroprotection against the vaccine strain lasted for at least two years, and most vaccinees also proved to be protected against the non-vaccine JEV genotypes at follow-up. Yet the seroprotection rates against the emerging genotype, GI, were no higher than 73%, suggesting that the booster vaccination should not be delayed beyond two years. As for travelers with a history of JE-MB primary series, a single dose of

JE-VC provided cross-reactive learn more seroprotection against strains of all major genotypes, including GI, for at least two years after the booster. This further encourages the use of a single heterologous JE-VC dose for boosting JE-MB immunity. While our results suggest that the next booster dose can be administered even after the prescribed 24-month interval, new studies are needed to establish the optimal timing. This work was financially supported by the Finnish Cultural these Foundation, Finska Läkaresällskapet, the Maud Kuistila Memorial Foundation and the Finnish Foundation for Research on Viral Diseases. A.K. and L.R. have participated as members in an advisory board for and received honoraria from Novartis and L.L. and L.R. from Baxter. A.K. has acted as a consultant on vaccination immunology and received research funds

from Crucell. A.K., L.L., J.R. and L.R. have received honoraria for lectures from Crucell, GlaxoSmithKline, Baxter and Pfizer. All other authors report no potential conflicts of interest. The authors thank the personnel of the Aava Travel Clinic, Aava Medical Centre, Finland and Cityakuten/Wasavaccination, Sweden for help in collecting blood samples and recruiting patients. “
“Serogroup B meningococci (MenB) account for 50–80% of invasive meningococcal disease (IMD) in Canada, with the highest incidence seen in children <5 years of age [1] and [2]. Despite the need for prevention, efforts to develop a vaccine against MenB disease have been hampered by the similarity of the polysaccharide capsule of the bacterium to human fetal neural tissue [3] and [4] and the inability to identify common protective surface antigens among MenB strains.